Polyclonal Antibody to Cadherin EGF LAG Seven Pass G-Type Receptor 3 (CELSR3)
| Code | Size | Price |
|---|
| PAG434Hu01-20ul | 20ul | £87.00 |
Quantity:
| PAG434Hu01-100ul | 100ul | £162.00 |
Quantity:
| PAG434Hu01-200ul | 200ul | £218.00 |
Quantity:
| PAG434Hu01-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CDHF11; EGFL1; FMI1; HFMI1; MEGF2; RESDA1; Cadherin family member 11; Epidermal growth factor-like protein 1; Multiple epidermal growth factor-like domains protein 2
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Cadherin EGF LAG Seven Pass G-Type Receptor 3
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Cadherin EGF LAG Seven Pass G-Type Receptor 3 (CELSR3) | RPG434Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||